Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Escitalopram + fludrocortisone is a combination of two pharmaceutical agents, each with distinct mechanisms of action. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) primarily used to treat major depressive disorder and generalized anxiety disorder by increasing serotonin levels in the brain through inhibition of the serotonin transporter. Fludrocortisone is a synthetic corticosteroid with potent mineralocorticoid activity, used mainly for conditions such as Addison’s disease and orthostatic hypotension; it acts by promoting sodium retention and increasing extracellular fluid volume via activation of the mineralocorticoid receptor. The combination has been studied in clinical research as an adjunctive therapy for major depression, where fludrocortisone may accelerate antidepressant response when added to escitalopram[3][6][7]. There are no known direct pharmacokinetic or pharmacodynamic interactions between these two drugs[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on escitalopram + fludrocortisone.